Clinical Updates & Insights

Our clinical updates provide you with timely information about Memorial Sloan Kettering’s new treatment approaches, key clinical trials, and innovations in detecting and treating many cancers.

Stay Informed
Get the latest information on MSK’s cancer treatments and research sent straight to your inbox with our monthly clinical updates e-newsletter OncoNotes.
Newsletter Sign Up
233 Clinical Updates found
Exciting New CAR T Cell Therapy Trial Opens at MSK

The effects of adoptive T cell therapy on mesothelioma and metastatic lung and breast cancers are the focus of a new Memorial Sloan Kettering Cancer Center trial, which, compared to some existing trials of therapy, offers some important differences for patients.
New Strides in Esophageal Cancer Management

Minimally invasive techniques, improved postoperative care, and a multidisciplinary approach help make Memorial Sloan Kettering Cancer Center’s rates of esophageal surgical morbidity and mortality among the country’s lowest.
The ALCHEMIST Trial for Lung Cancer Patients

To explore new treatment options – and potentially change the standard of care for resected lung cancer – Memorial Sloan Kettering Cancer Center is enrolling patients in a National Cancer Institute-sponsored trial.
Advanced Ovarian Cancer: Balancing Treatment Risks and Benefits

In contrast with the findings of two international trials, Memorial Sloan Kettering Cancer Center data suggest the standard treatment – primary debulking surgery – may provide better outcomes in select patients when compared to neoadjuvant chemotherapy.
Managing the Inherited Risk of Ovarian Cancer

Risk-reducing salpingo-oophorectomy brings on early menopause and its attendant consequences. Researchers are exploring whether a less drastic surgical strategy can offer a safe and efficacious option.
Trials for Two New Immunotherapies

Immune checkpoint inhibitors and adoptive T cell therapy have shown success in treating several cancers. Now both approaches are in trials for gynecologic cancers, and researchers think even more applications are possible.
A New Era in Axillary Management for Node-Positive Women

After two studies examined the safety of eliminating axillary lymph node dissection (ALND) for some breast cancer patients, Memorial Sloan Kettering Cancer Center further tested their conclusions, confirmed the approach’s applicability and changed clinical practice.
Better Screening, Less Cost

Mammography has shortcomings but the price is reasonable; MRI is more effective but expensive. Two new modalities — contrast-enhanced digital mammography (CEDM) and abbreviated breast MRI (AB-MRI) — may provide the best of both.
Is Low Risk DCIS Really Low Risk?

Research at Memorial Sloan Kettering Cancer Center suggests that what’s usually considered low-risk ductal carcinoma in situ (DCIS) may still present significant risk. Two European trials comparing observation to surgical excision for women with low-risk DCIS are expected to provide important additional data.
Targeting Estrogen Receptors

About a third of patients with metastatic breast cancer don’t respond well to the standard anti-estrogen therapies; to find ways to better treat those patients, Memorial Sloan Kettering Cancer Center is studying three new selective estrogen receptor down-regulators (SERDs) in clinical trials.